Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Novartis ends ALS program after phase 2 flop, adding to R&D woes
(19h)
Novartis pays Sironax $125M to acquire platform for crossing the blood-brain barrier
(21h)
Sling reels in $123M series C to fund oral Tepezza rival through phase 3 trial
(1d)
BioPharma Dive
Novartis to pay $125M for blood-brain barrier crossing platform
(13h)
Novo looks to Anthropic’s AI models to ‘supercharge’ drug development
(18h)
Sling banks $123M for an experimental thyroid eye disease pill
(18h)
Endpoints News
Drugmakers cooperate with House probe of China trial sites
(15h)
FDA faces questions on 'America First' provisions in latest user fee agreement
(16h)
Gilead reaches HIV PrEP agreements; Hong Kong investigates Cloudbreak IPO
(18h)
BioSpace
Biopharma hiring hotspots: States, disciplines where demand is highest
(2h)
Trending: Top biopharma disciplines with jobs live now
(2h)
FDA warning letter accuses Bausch & Lomb of lacking commitment to remediation
(19h)
STAT News
The FDA’s rebuilding effort is running into a new challenge
(1h)
What happened to oppositional defiant disorder?
(1h)
England to cover AstraZeneca breast cancer drug, a result of U.K.-U.S. drug pricing deal
(2h)
BioPharma Trend
The Bigger Point Beyond Insilico's Aging Research Milestone
(1w)
The Measurement Challenge in Longevity: Can Aging Biomarkers and Clocks Close the Gap?
(1w)
What the New AI Model Releases by Anthropic and OpenAI Change for Life Sciences
(2w)
Drug Channels
Preorder DCI’s New 2026-27 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors
(2d)
Informa Connect’s Pharma/Biotech GTN Summit
(3d)
Drug Channels Leadership Forum 2027: Antonio Ciaccia to Serve as Moderator
(1w)
European Biotechnology Magazine
SLAS Journals Spotlight AI in Drug Discovery
(2h)
Sensorion files confidentially for potential U.S. IPO
(18h)
The Strüngmann legacy, passed on
(1d)
Drug Hunter
enpatoran (M5049)
(19h)
pociredir
(1d)
How Pyridazinones Mimic Amides, Phenols, and Nicotinamides
(2d)
Labiotech.EU
Oncology biotech news: key moves to watch in September 2026
(21h)
New non-opioid pain medication: How is the biotech industry fighting pain after the opioid crisis?
(1d)
BIOSPAIN 2026: Spain’s flagship biotech event is going annual
(2d)
Bio IT World
A 1970s Lipid-Lowering Compound May Offer a New Approach to Obesity
(1d)
Lehigh Team Uses Digital Twin of Gut-Brain Axis to Advance Neurostimulation Therapies
(2d)
What It Takes to Make Generative AI Fit for GMP
(6d)
GEN News
Brain Protein in Mice Offers Insights Into Brain Development and ADHD
(13h)
Prophylactic Phage Therapy Protects Mice Against Oral Salmonella Infection
(14h)
Cellares and GenomeFrontier Therapeutics Partner to Advance Automated Manufacturing of GF-CART01
(15h)
Cure Today
Gentle Exercises to Keep You Moving During Cancer Treatment feat. Jennifer Tipton
(11h)
Imfinzi Plus Chemotherapy Raises 3-Year Survival to 69% in Gastric Cancer
(16h)
Childhood Leukemia Survivor Shares Her Experience With ALL, Relapse and CAR-T
(1d)
Contract Pharma
Gilead Partners With Pan American Health Organization on Lenacapavir Access for Latin America, Caribbean
(14h)
Thermo Fisher Launches SuperScript V Reverse Transcriptase
(14h)
Lilly TuneLab, Twist Bioscience Partner on Antibody Drug Discovery - contractpharma.com
(17h)
Pharma Times
Jemperli accepted for priority review by US FDA
(2w)
Carterra supports AI‑designed protein study with HT-SPR platforms
(2w)
Erasca secures FDA fast track for eras‑0015 in pancreatic cancer
(3w)
Medcity News
Novartis Gains a Way to Get Drugs Into the Brain, Buying Sironax Tech for $125M
(15h)
As MA Denial Rates Rise, Hospitals Are Betting on Traditional Medicare Instead
(17h)
AI Isn’t a Therapist, but Many Teens Are Treating It Like One
(19h)
Chemical & Engineering News
Why the Reflecting Pool coating peeled and blistered
(12h)
What did a group of Priestly Medalists have to say about the future of chemistry?
(18h)
Comment: Building stronger local sections for the future
(20h)
The Pharma Letter
Boehringer halts Phase III kidney trial of vicadrostat/Jardiance combination
(49m)
ICER releases evidence report on treatment for Parkinson’s disease
(16h)
Vivan and Ad Atomica pair tumor genotype data with AI drug design
(16h)
Targeted Oncology
After the First ADC Fails, HR-Positive Breast Cancer Sequencing Runs on Judgment, Not Trial Data
(12h)
Tam-Peli Extends Survival in Relapsed Small Cell Lung Cancer
(15h)
FDA Accepts Bezuclastinib NDA for Advanced Systemic Mastocytosis
(17h)
MedWatch
Lundbeck Foundation secures more votes through share exchange
(26m)
New CEO appointment eases strategy concerns at Bavarian Nordic, Jefferies says
(27m)
Bavarian Nordic names new CEO
(47m)
In The Pipeline
The ACS Redesign
(1d)
Not The Glue They Thought It Was
(2d)
The State of AI Antibody Design
(5d)
Pharmaphorum
NICE finally backs Enhertu for HER2-low breast cancer
(35m)
Novo taps Anthropic's Claude AI for drug discovery
(1h)
Wales takes UK lead on needle-free anaphylaxis prevention
(17h)
Drug Discovery Weekly
Wegovy pill could help patients lose 17% body weight
(3mo)
How AskBio is pioneering ‘transformative genetic therapies’ in Parkinson’s disease
(3mo)
Webinar: Learn how to accelerate the early stages of drug discovery
(3mo)
HIT Consultant
M&A: Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care
(15h)
Biohacking’s Gender Problem: Why Women’s Health Protocols Require Dedicated Research and Clinical Variables
(18h)
R1 Unveils Phare Utilization Management on Phare OS to Eliminate Medical Necessity Denials
(18h)
Insights: Pink Sheet
No Letup In Aging Japan’s Rising Health, Drug Costs
(6h)
OTC Industry Makes First PDUFA Appearance After Months of Behind-the-Scenes Negotiations
(9h)
Big Pharma CEOs Bullish On US Policy Environment Heading Into Midterm Elections
(11h)
BioXconomy
FDA to boost overseas trial site inspections amid concerns about regulatory oversight capacity
(12h)
RegCell banks $66m to advance Nobel-winning immune tolerance platform
(17h)
Japan’s hybrid DCT approach shaped by unique regulations, healthcare system, and geography
(18h)
BioCentury
Academic deals stay close to home
(9h)
Science Spotlight: A macrophage-recruiting bispecific, plus new tactics against TCR-T escape and tumor stroma
(12h)
Sleep deals cluster in narcolepsy and sleep apnea
(13h)
SCRIP
Roivant’s Push To Become More Than A Pipeline Story
(46m)
Amgen Confident In Cardiometabolic Pipeline After Novartis’s Negative Lp(a) Readout
(11h)
Novartis’s VHB937 Latest To Join ALS Clinical Development Graveyard
(12h)